Psoriatic arthritis from a mechanistic perspective
- PMID: 35513599
- DOI: 10.1038/s41584-022-00776-6
Psoriatic arthritis from a mechanistic perspective
Abstract
Psoriatic arthritis (PsA) is part of a group of closely related clinical phenotypes ('psoriatic disease') that is defined by shared molecular pathogenesis resulting in excessive, prolonged inflammation in the various tissues affected, such as the skin, the entheses or the joints. Psoriatic disease comprises a set of specific drivers that promote an aberrant immune response and the consequent development of chronic disease that necessitates therapeutic intervention. These drivers include genetic, biomechanical, metabolic and microbial factors that facilitate a robust and continuous mobilization, trafficking and homing of immune cells into the target tissues. The role of genetic variants involved in the immune response, the contribution of mechanical factors triggering an exaggerated inflammatory response (mechanoinflammation), the impact of adipose tissue and altered lipid metabolism and the influence of intestinal dysbiosis in the disease process are discussed. Furthermore, the role of key cytokines, such as IL-23, IL-17 and TNF, in orchestrating the various phases of the inflammatory disease process and as therapeutic targets in PsA is reviewed. Finally, the nature and the mechanisms of inflammatory tissue responses inherent to PsA are summarized.
© 2022. Springer Nature Limited.
Similar articles
-
[New aspects on the pathogenesis of psoriatic arthritis].Z Rheumatol. 2013 Oct;72(8):758-63. doi: 10.1007/s00393-013-1186-x. Z Rheumatol. 2013. PMID: 24046231 German.
-
Immune regulation in psoriasis and psoriatic arthritis--recent developments.Immunol Lett. 2007 Dec 15;114(2):59-65. doi: 10.1016/j.imlet.2007.08.009. Epub 2007 Sep 25. Immunol Lett. 2007. PMID: 17928070 Review.
-
Psoriatic arthritis: tissue-directed inflammation?Clin Rheumatol. 2018 Apr;37(4):859-868. doi: 10.1007/s10067-018-4012-7. Epub 2018 Feb 23. Clin Rheumatol. 2018. PMID: 29476352 Review.
-
PET/CT-Based Characterization of 18F-FDG Uptake in Various Tissues Reveals Novel Potential Contributions to Coronary Artery Disease in Psoriatic Arthritis.Front Immunol. 2022 Jun 2;13:909760. doi: 10.3389/fimmu.2022.909760. eCollection 2022. Front Immunol. 2022. PMID: 35720288 Free PMC article.
-
A glimpse on the role of IL-21 in psoriatic arthritis pathogenesis.Life Sci. 2024 Aug 1;350:122766. doi: 10.1016/j.lfs.2024.122766. Epub 2024 Jun 2. Life Sci. 2024. PMID: 38834097 Review.
Cited by
-
Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study.J Pers Med. 2024 Jul 3;14(7):716. doi: 10.3390/jpm14070716. J Pers Med. 2024. PMID: 39063970 Free PMC article.
-
Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes.Front Med (Lausanne). 2022 Jul 27;9:934937. doi: 10.3389/fmed.2022.934937. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35966881 Free PMC article.
-
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment.Int J Mol Sci. 2023 Jul 19;24(14):11662. doi: 10.3390/ijms241411662. Int J Mol Sci. 2023. PMID: 37511421 Free PMC article. Review.
-
Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement-Monocentric Real-World Evidence.J Clin Med. 2025 May 1;14(9):3151. doi: 10.3390/jcm14093151. J Clin Med. 2025. PMID: 40364181 Free PMC article.
-
Subclinical psoriatic arthritis and disease interception-where are we in 2024?Rheumatology (Oxford). 2025 Jan 1;64(1):56-64. doi: 10.1093/rheumatology/keae399. Rheumatology (Oxford). 2025. PMID: 39150442 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous